American Oriental Bioengineering (广西博科药业) will begin a US-based Phase I clinical trial of its oral TCM treatment for urinary incontinence, designed to gain approval of the drug from the FDA. AOB has marketed the UI drug in China since 2002 under the name Cease Enuresis Oral Capsule. The IND was based on pre-clinical work done in China to FDA standards. The clinical trials will be conducted in the US and China, though its goal is to show that AOBO-001, as the trial version is known, is effective for UI in American populations. More details...

Stock Symbol: (NYSE: AOB)